Altimmune CFO Richard Eisenstadt dies unexpectedly; Andrew Shutterly named acting CFO

Altimmune, Inc.

Richard Eisenstadt, CFO, passed away unexpectedly on June 24, 2024.
Andrew Shutterly appointed acting CFO effective June 25, 2024; previously Corporate Controller since Feb 2023.
Company has initiated a search for a permanent replacement CFO.
Shutterly joined Altimmune in Oct 2020 as Assistant Controller; prior roles at Meso Scale Diagnostics and Deloitte.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Richard Eisenstadt

Chief Financial Officer

ALT · Altimmune, Inc.

Effective: 2024-06-24
Successor: Andrew Shutterly
Filed: June 26, 2024, 7:59 PM ET

following the unexpected death of Richard Eisenstadt, the Company’s Chief Financial Officer.

Appointed (interim)

Andrew Shutterly

acting Chief Financial Officer

ALT · Altimmune, Inc.

Effective: 2024-06-25
Filed: June 26, 2024, 7:59 PM ET

appointed Andrew Shutterly as acting Chief Financial Officer

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Richard Eisenstadt departed as Chief Financial Officer at Altimmune, Inc..

Role: Chief Financial Officer

Exact text from the filing

following the unexpected death of Richard Eisenstadt, the Company’s Chief Financial Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Andrew Shutterly was appointed as acting Chief Financial Officer at Altimmune, Inc..

Action: appointed
Role: acting Chief Financial Officer

Exact text from the filing

appointed Andrew Shutterly as acting Chief Financial Officer

View on SEC.gov

Altimmune, Inc. filing history →

Source: SEC EDGAR

accession 0001326190-24-000022

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.